All In Biotech

Drug Trial Radar · NCT03774056

A Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of HC-1119 in Patients.

A Phase I Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of HC-1119 in Patients With Metastatic Castration-Resistant Prostate Cancer.

Last checked: Nov 20, 2026Latest source record: Nov 3, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

43

Actual

Start

Feb 10, 2017

Primary completion

Sep 26, 2018

Study completion Aug 28, 2019

Sponsor

Lead sponsor
Hinova Pharmaceuticals Inc.Industry
Sponsor type
Industry
Collaborators
West China Hospital
First posted
Dec 12, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase I study evaluating tolerability, pharmacokinetics, and preliminary efficacy of HC-1119 in patients with metastatic castration-resistant prostate cancer. The study objective is to study the tolerability, safety, and dose-limiting toxicities (DLT) of HC-1119 in patients with mCRPC.

Conditions

  • Metastatic Castration Resistant Prostate Cancer

Interventions

  • HC-1119Drug

    oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicities(DLT)Time frame: From the first dose of the study to the 12th week after dose
  2. Number of patients with adverse eventsTime frame: From the first dose of the study to the 12th week after dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hinova Pharmaceuticals Inc.

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.